Viking Therapeutics Revenue 2011-2026 | VKTX

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Viking Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	10.7 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
10.7 K	10.7 K	10.7 K

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Alterity Therapeutics Limited ATHE	109 K	$ 3.6	1.34 %	$ 8.66 B	Australia
Aytu BioScience AYTU	66.4 M	$ 2.66	-	$ 16.7 M	USA
BioNTech SE BNTX	482 M	$ 91.28	-	$ 27.2 B	Germany
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Burford Capital Limited BUR	330 M	$ 4.48	-	$ 736 M	Britain
Cerus Corporation CERS	234 M	$ 1.85	-	$ 353 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Coherus BioSciences CHRS	42.2 M	$ 1.67	-	$ 196 M	USA
Celldex Therapeutics CLDX	1.54 M	$ 31.37	-	$ 2.08 B	USA
CollPlant Biotechnologies Ltd. CLGN	15.6 M	$ 0.44	-	$ 5.04 M	Israel
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Catalyst Pharmaceuticals CPRX	589 M	$ 24.98	-	$ 3.05 B	USA
Corbus Pharmaceuticals Holdings CRBP	882 K	$ 10.14	-	$ 135 M	USA
Cardiff Oncology CRDF	593 K	$ 1.58	-	$ 106 M	USA
Curis CRIS	9.44 M	$ 0.53	-	$ 6.98 M	USA
Crinetics Pharmaceuticals CRNX	7.7 M	$ 37.7	-	$ 3.55 B	USA
CRISPR Therapeutics AG CRSP	3.51 M	$ 49.15	-	$ 4.42 B	Schweiz
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
CytomX Therapeutics CTMX	76.2 M	$ 4.4	-	$ 607 M	USA
Citius Pharmaceuticals CTXR	90 K	$ 0.86	-	$ 5.79 M	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Cue Biopharma CUE	27.5 M	$ 0.18	-	$ 17.1 M	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
DBV Technologies S.A. DBVT	5.64 M	$ 20.36	-	$ 2.84 B	France
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Denali Therapeutics DNLI	331 M	$ 19.38	-	$ 3.19 B	USA
Dyadic International DYAI	3.09 M	$ 0.87	-2.8 %	$ 31.5 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Entera Bio Ltd. ENTX	365 K	$ 1.19	-	$ 55.5 M	Israel
Equillium EQ	41.1 M	$ 2.01	-	$ 115 M	USA
Alnylam Pharmaceuticals ALNY	3.71 B	$ 330.34	-	$ 43.3 B	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Fate Therapeutics FATE	6.65 M	$ 1.19	-	$ 141 M	USA